Abstract
Background Mammographic (or breast) density is an established risk factor for breast cancer. There are a variety of approaches to measurement including quantitative, semi-automated and automated approaches. We present a new automated measure, AutoCumulus, learnt from applying deep learning to semi-automated measures.
Methods We used mammograms of 9,057 population-screened women in the BRAIx study for which semi-automated measurements of mammographic density had been made by experienced readers using the CUMULUS software. The dataset was split into training, testing, and validation sets (80%, 10%, 10%, respectively). We applied a deep learning regression model (fine-tuned ConvNeXtSmall) to estimate percentage density and assessed performance by the correlation between estimated and measured percent density and a Bland-Altman plot. The automated measure was tested on an independent CSAW-CC dataset in which density had been measured using the LIBRA software, comparing measures for left and right breasts, sensitivity for high sensitivity, and areas under the receiver operating characteristic curve (AUCs).
Results Based on the testing dataset, the correlation in percent density between the automated and human measures was 0.95, and the differences were only slightly larger for women with higher density. Based on the CSAW-CC dataset, AltoCumulus outperformed LIBRA in correlation between left and right breast (0.95 versus 0.79; P<0.001), specificity for 95% sensitivity (13% versus 10% (P<0.001)), and AUC (0.638 cf. 0.597; P<0.001).
Conclusion We have created an automated measure of mammographic density that is accurate and gives superior performance on repeatability within a woman, and for prediction of interval cancers, than another well-established automated measure.
Competing Interest Statement
The authors have declared no competing interest.
Funding Statement
This work was supported by grants from the Australian Government Medical Research Future Fund (MRFAI000090), the Cancer Council Victoria (AF7305) and the National Breast Cancer Foundation (IIRS-18-093). JLH was supported by an NHMRC Fellowship grant (GMT1137349), SL was supported by a Victoria Cancer Agency Early Career grant (ECRF19020) and an NHMRC Emerging Leadership Fellowship (GNT2017373), and GC was supported by an ARC Future Fellowship grant (FT190100525).
Author Declarations
I confirm all relevant ethical guidelines have been followed, and any necessary IRB and/or ethics committee approvals have been obtained.
Yes
I confirm that all necessary patient/participant consent has been obtained and the appropriate institutional forms have been archived, and that any patient/participant/sample identifiers included were not known to anyone (e.g., hospital staff, patients or participants themselves) outside the research group so cannot be used to identify individuals.
Yes
I understand that all clinical trials and any other prospective interventional studies must be registered with an ICMJE-approved registry, such as ClinicalTrials.gov. I confirm that any such study reported in the manuscript has been registered and the trial registration ID is provided (note: if posting a prospective study registered retrospectively, please provide a statement in the trial ID field explaining why the study was not registered in advance).
Yes
I have followed all appropriate research reporting guidelines, such as any relevant EQUATOR Network research reporting checklist(s) and other pertinent material, if applicable.
Yes
Data Availability
All data produced in the present study are available upon reasonable request to the authors
